EC Aware (@ECAware) header
EC Aware (@ECAware) profile picture

EC Aware

@ECAware

A grass-roots not for profit organization on a mission to reduce the incidence and impact of Esophageal Cancer

 worldwide
ecaware.org
Joined May 2010
  • Tweets8.4K
  • Following1.3K
  • Followers1.1K
clinicaltrialsarena.com/news…
ESMO26: Novel combo successes signal shift from frontline chemo in cold cancers

ESMO26: Novel combo successes signal shift from frontline chemo in cold cancers

While there has been a shift to new modalities in “hot” cancers, chemotherapy has remained steadfast in the first line for “cold” tumours – but this is changing, say experts at ESMO26.

clinicaltrialsarena.com
13
oncodaily.com/opinion/arion-…
ARION Trial Shows No Progression-Free Survival Benefit From Adding Durvalumab to Definitive...

ARION Trial Shows No Progression-Free Survival Benefit From Adding Durvalumab to Definitive...

ARION Trial Shows No Progression-Free Survival Benefit From Adding Durvalumab to Definitive Chemoradiotherapy in Esophageal Cancer / ARION Trial, definitive

oncodaily.com
29
esmo.org/insights-by-esmo/al…
34
medpagetoday.com/opinion/pat…
Opinion | Prior Authorization Denied

Opinion | Prior Authorization Denied

It's time to flip the system, and make insurers carry the burden of proof

medpagetoday.com
1
33
oncodaily.com/voices/elizabe…
Elizabeth Smyth: ESMO Updates Clinical Practice Guidelines for Gastric and Oesophageal Cancer -...

Elizabeth Smyth: ESMO Updates Clinical Practice Guidelines for Gastric and Oesophageal Cancer -...

Elizabeth Smyth: ESMO Updates Clinical Practice Guidelines for Gastric and Oesophageal Cancer / cancer, Elizabeth Smyth, ESMO, gastric cancer, OncoDaily,

oncodaily.com
15
prnewswire.com/news-releases…
Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-L...

Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-L...

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced updated overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial evaluating...

prnewswire.com
47
news.unchealthcare.org/2026/…
UNC Researchers Investigate Why Some Stomach and Esophageal Cancers Resist Immunotherapy | Newsroom

UNC Researchers Investigate Why Some Stomach and Esophageal Cancers Resist Immunotherapy | Newsroom

A $3 million grant from the Mark Foundation will help a team of UNC School of Medicine experts identify ways to solve immunotherapy resistance, a growing problem in patients with stomach and esopha...

news.unchealthcare.org
26
bioengineer.org/lymph-node-s…
Lymph Node Status After Chemoimmunotherapy Predicts Survival in Esophageal

Lymph Node Status After Chemoimmunotherapy Predicts Survival in Esophageal

A retrospective cohort study of 194 patients with esophageal squamous cell carcinoma found that postoperative pathological lymph node stage, rather than pre-treatment clinical node status, was the...

bioengineer.org
16
oncodaily.com/oncolibrary/ra…
Can Surgery Be Avoided After Chemoradiotherapy for Esophageal Cancer? Long-Term SANO Trial Results...

Can Surgery Be Avoided After Chemoradiotherapy for Esophageal Cancer? Long-Term SANO Trial Results...

Can Surgery Be Avoided After Chemoradiotherapy for Esophageal Cancer? Long-Term SANO Trial Results / chemoradiotherapy, esmo 2026, ESMO 26, esophageal cancer,

oncodaily.com
21
medscape.com/viewarticle/act…
20
consumeraffairs.com/news/hot…
Hot drinks may come with a cancer risk few coffee drinkers consider

Hot drinks may come with a cancer risk few coffee drinkers consider

Drinking beverages at very hot temperatures was linked to a higher risk of one type of esophageal cancer.People drinking six or more hot drinks a day also

consumeraffairs.com
21
bioengineer.org/immunotherap…
Immunotherapy, AI and an Aging Population Are Rewriting Esophageal Cancer

Immunotherapy, AI and an Aging Population Are Rewriting Esophageal Cancer

Esophageal cancer has long been one of the most lethal and unforgiving of the major malignancies, but the ground beneath the surgeon’s feet is shifting faster now than at any point in the past two...

bioengineer.org
22
auntminnie.com/resources/con…
ASTRO: How does tumor location affect survival in patients with esophageal cancer?

ASTRO: How does tumor location affect survival in patients with esophageal cancer?

Upper esophageal tumors were associated with the best survival, while middle esophageal location carried significantly worse odds.

auntminnie.com
35
koreabiomed.com/news/article…
Opdivo moves closer to Korea coverage in esophageal, liver cancers, setting up price battle - Korea...

Opdivo moves closer to Korea coverage in esophageal, liver cancers, setting up price battle - Korea...

Bristol Myers Squibb's immunotherapy Opdivo (nivolumab) has cleared a key hurdle toward expanded reimbursement in Korea for first-line treatment of esophageal squamous cell carcinoma and hepatocell...

koreabiomed.com
22
nature.com/articles/s41467-0…
First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in unresectable advanc...

First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in unresectable advanc...

Nature Communications - The RATIONALE-306 trial demonstrated improved overall survival in participants with advanced/metastatic esophageal squamous cell carcinoma treated with tislelizumab plus...

nature.com
30
health.yahoo.com/conditions/…
How much alcohol it takes to increase your risk of dying of 9 cancers: study

How much alcohol it takes to increase your risk of dying of 9 cancers: study

A bottle a day probably won’t keep the doctor at bay.

health.yahoo.com
1
22
oncodaily.com/oncolibrary/im…
RATIONALE-306: Tislelizumab Plus Chemotherapy Shows Sustained 3-Year Survival Benefit in Advanced...

RATIONALE-306: Tislelizumab Plus Chemotherapy Shows Sustained 3-Year Survival Benefit in Advanced...

RATIONALE-306: Tislelizumab Plus Chemotherapy Shows Sustained 3-Year Survival Benefit in Advanced ESCC / biomarker analysis, chemoimmunotherapy, clinical

oncodaily.com
32
nature.com/articles/s41388-0…
ITGA5 promotes homologous recombination mediated radioresistance in esophageal squamous cell...

ITGA5 promotes homologous recombination mediated radioresistance in esophageal squamous cell...

Oncogene - ITGA5 promotes homologous recombination mediated radioresistance in esophageal squamous cell carcinoma by upregulating RAD51AP1 expression

nature.com
26
sciencedaily.com/releases/20…
Scientists find breast cancer cells hiding behind protective “shields”

Scientists find breast cancer cells hiding behind protective “shields”

Researchers have mapped breast tumors in striking detail and uncovered hidden pockets of dormant cancer cells that may help explain why cancer can return after treatment. Unlike rapidly dividing...

sciencedaily.com
28
targetedonc.com/view/growing…
Growing Alcohol-Attributable Cancer Burden in US Reveals Prevention Gap | Targeted Oncology -...

Growing Alcohol-Attributable Cancer Burden in US Reveals Prevention Gap | Targeted Oncology -...

U.S. alcohol-linked cancer deaths double since 1990, led by surging liver cancer; men, older adults hit hardest, with wide state-by-state gaps.

targetedonc.com
24
Load more